Sponsored Webcast: The Preparation Process for CHMP Meetings

RAC Credits
Wednesday, 12 September 2018 (12:00 PM) - Wednesday, 12 September 2018 (1:30 PM) (Eastern Time (US & Canada))

12 September 2018

12:00 – 1:30 pm EDT

Getting a product approved by the European Medicines Agency (EMA) can be daunting, especially for companies that have little experience with this unique and complex process. Within the EMA, the Committee for Medicinal Products for Human Use (CHMP) conducts a scientific data review and recommends whether or not the drug or biologic should receive marketing authorization.  

This webcast will walk you through how to prepare for and manage CHMP meetings, as well as how to identify and address issues prior to submission.    

Learning Level

Intermediate: Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.  

Learning Objectives 

Upon the webcast's conclusion, you will be able to:  

  • Define the EMA review timeline
  • Evaluate how to prepare for the four different types of CHMP meetings you may face 
    • Expert Group meeting
    • Scientific Advisory Group (SAG) meeting
    • Oral Explanation
    • Pharmacovigilance Risk Assessment Committee (PRAC) meeting
  • Discuss pre-submission activities that will help identify and avoid issues 

Who should attend?

  • Companies seeking to get products approved by European Medicines Agency (EMA)


Kell Cannon, principal, 3D Communications

Kell Cannon brings more than 20 years of U.S. and global lifecycle and pharmaceutical marketing expertise to 3D's clients. Cannon uses his analytical and organizational skills to help clients identify the strengths and weaknesses in their data and define their competitive differentiation. He has developed rigorous processes to help clients analyze and prepare their regulatory submissions and FDA advisory committee presentations. This assistance enables companies to win approval, expedite product access and achieve competitive reimbursement. Cannon has held leadership positions at Roche, Novartis, Ciba and Merck in clinical trial strategy, label negotiations, brand positioning and advocacy development.